Goldman Sachs Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $52
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Corinne Jenkins has reaffirmed a Buy rating on Rhythm Pharmaceuticals (NASDAQ:RYTM) and increased the price target from $42 to $52.
January 26, 2024 | 2:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs analyst Corinne Jenkins maintains a Buy rating on Rhythm Pharmaceuticals and raises the price target from $42 to $52.
The increase in price target by a reputable investment bank like Goldman Sachs typically signals a strong conviction in the company's future performance. This can lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100